SCHEMBL419264

SCHEMBL419264

O=C(O)C(=O)N1CCOCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA9 Q16790 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MEN1 O00255 1/20 0.52
TP53 P04637 1/20 0.52
KMT2A Q03164 1/20 0.52
MMP1 P03956 1/20 0.50
MMP3 P08254 1/20 0.50
MMP8 P22894 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
HTT P42858 2/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.44
CA2 P00918 1/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
AKR1C3 P42330 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL786679 0.88 SMN1; SMN2 (0.59) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL30839283 0.84 SMN1; SMN2 (0.45) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL24117660 0.82 SMN1; SMN2 (0.48) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL30511277 0.81 SMN1; SMN2 (0.52) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL6040035 0.81 MEN1 (0.62) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL27840293 0.80 CA12 (0.56) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL55421 0.80
SCHEMBL7328541 0.79 SMN1; SMN2 (0.62) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL15125184 0.79 SMN1; SMN2 (0.50) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL22234568 0.79 CA12 (0.50) CA12CA1CA9SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392371-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2019-08-27 US claimed
US-8344025-B2 Oxalic acid derivatives and use thereof as physiological cooling active ingredients SYMRISE AG (DE) 2013-01-01 US claimed
US-20090054520-A1 OXALIC ACID DERIVATIVES AND USE THEREOF AS PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS SYMRISE GMBH & CO. KG (DE) 2009-02-26 US claimed
WO-2025060911-A1 SUBSTITUTED PYRIDOTRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 成都奥睿药业有限公司 2025-03-27 WO disclosed
WO-2025001687-A1 Α-KETO ACID AMIDE OR SUBSTITUTED OXALIC ACID AMIDE ESTER COMPOUND AND COMPOSITION THEREOF 南京桦冠生物技术有限公司 2025-01-02 WO disclosed
CN-118878535-A Substituted pyridotriazole compound, preparation method and application thereof 成都奥睿药业有限公司 2024-11-01 CN disclosed
CN-115403519-B Synthesis method of N-substituted isonicotinamide compound driven by visible light 河南师范大学 2024-03-01 CN disclosed
CN-115521275-B Method for preparing oxamide compounds by using gold-based catalyst 中国科学院兰州化学物理研究所 2024-01-05 CN disclosed
CN-116554122-B Alpha-keto acid amide or substituted oxalic acid amide ester compound and composition thereof 南京桦冠生物技术有限公司 2023-09-19 CN disclosed
CN-116554122-A Alpha-keto acid amide or substituted oxalic acid amide ester compound and composition thereof 南京桦冠生物技术有限公司 2023-08-08 CN disclosed
CN-115521275-A Method for preparing oxamide compound by using gold-based catalyst 中国科学院兰州化学物理研究所 2022-12-27 CN disclosed
EP-2391212-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2011-12-07 EP disclosed
WO-2010088167-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-08-05 WO disclosed
CN-101646674-A The indoles and the benzoazepine derivative that are used for the treatment of hepatitis C SQUIBB BRISTOL MYERS CO US 2010-02-10 CN disclosed
EP-2114947-A1 INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C Brystol-Myers Squibb Company (US) 2009-11-11 EP disclosed
US-7541352-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-02 US disclosed
US-20090054520-A1 OXALIC ACID DERIVATIVES AND USE THEREOF AS PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS SYMRISE GMBH & CO. KG (DE) 2009-02-26 US disclosed
WO-2008097796-A1 INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-14 WO disclosed
US-20080188458-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2008-08-07 US disclosed
US-4022765-A ANTI-INFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1977-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188458-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 CA12 1778/4885CA1 4401/4885CA9 2697/4885
US-10392371-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM4, TRPM6 CA12 2758/4885CA1 1069/4885CA9 2359/4885
US-20090054520-A1 OXALIC ACID DERIVATIVES AND USE THEREOF AS PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS OTC, OAT, HOGA1 CA12 23/4885CA1 5/4885CA9 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.